-
Adjuvant Therapy in Non-Small-Cell Lung Cancer
In this expert column, Dr. Heather Wakelee examines the increasingly routine use of adjuvant therapy for patients with early stage non-small-cell lung cancer.
Expert Viewpoint, July 2008
-
Oral VEGF Therapies in Lung Cancer
This expert column explores the latest data on the use of oral VEGF therapies in lung cancer.
Expert Viewpoint, May 2008
-
Prevention and Treatment of Lymphedema Related to Breast Cancer
Although lymphedema associated with breast cancer treatment is not currently curable, early detection, treatment, and maintenance contribute to better outcomes.
Expert Viewpoint, December 2007
-
Novel Treatment Approaches for Patients With Early-Stage Non-Small-Cell Lung Cancer
Although not yet practice changing, lung cancer data presented at the 2007 ASCO meeting have interesting implications for adjuvant strategies in the early disease setting.
Expert Viewpoint, November 2007
-
Sex Differences in the Natural History and Treatment of NSCLC
Does sex play a role in lung cancer? Dr. Heather Wakelee explores the latest research in regard to differences in survival and treatment between women and men with lung cancer.
Expert Viewpoint, September 2007
-
Rationale, Design, and Results of Clinical Trials Combining Radiotherapy With Antiangiogenic Therapy in Rectal Cancer
Drs. Brian Czito and Christopher Willett explore the optimal approaches to integrating antiangiogenic agents into chemoradiation therapy for rectal cancer.
Expert Viewpoint, September 2007
-
Skin Rash Associated With EGFR Inhibitors: A Marker of Therapeutic Efficacy
Dr. Missak Haigentz, Jr., addresses clinical observations and theory about the link between rash and the anticancer activity of EGFR inhibitors in patients with NSCLC and other cancers.
Expert Viewpoint, July 2007
-
Perspectives on Novel Therapies for Advanced Non-Small-Cell Lung Cancer
Clinical implications of data from trials with targeted agents in NSCLC are reviewed and discussed in this Expert Column.
Expert Viewpoint, April 2007
-
Clinical Considerations in Adjuvant Treatment of HER2-Positive Breast Cancer
Dr. Edward Romond offers an expert perspective on optimal use of trastuzumab in patients with early HER2-positive breast cancer.
Expert Viewpoint, October 2006
-
Targeted Therapy in NSCLC: The Role of Epidermal Growth Factor Receptor Mutations
In this Expert Column, Pasi Janne, MD, reviews studies of molecular predictors of response to EGFR TKIs in the treatment of non-small-cell lung cancer.
Expert Viewpoint, August 2006
-
Targeting VEGF: A Promising Approach to Improving Outcomes in Advanced Breast Cancer
Kathy Miller, MD, and John Salter, MD, review the latest understanding in the use of anti-VEGF therapy for advanced breast cancer.
Expert Viewpoint, June 2006
-
The Potential Use of Targeted Agents for the Treatment of Colorectal Cancer in the Adjuvant Setting
Following on the success of biologic agents in advanced colorectal cancer, research has turned to the adjuvant setting. M. Wasif Saif, MD, highlights some of the ongoing studies.
Expert Viewpoint, January 2006
-
Combining Biologic Agents for Treatment of Metastatic Colorectal Cancer: Rationale and Results
In this Expert Column, Drs. Paulo Hoff and Everardo Saad discuss the rationale for combining bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Expert Viewpoint, December 2005
